PT - JOURNAL ARTICLE AU - Emilia Roy-Vallejo AU - Laura Cardeñoso AU - Ana Triguero-Martínez AU - Marta Chicot Llano AU - Nelly Zurita AU - Elena Ávalos AU - Ana Barrios AU - Julia Hernando AU - Javier Ortiz AU - Sebastián C. Rodríguez-García AU - Marianela Ciudad Sañudo AU - Celeste Marcos AU - Elena García Castillo AU - Leticia Fontán García-Rodrigo AU - Begoña González AU - Rosa Méndez AU - Isabel Iturrate AU - Ancor Sanz-García AU - Almudena Villa AU - Ana Sánchez Azofra AU - Begoña Quicios AU - David Arribas AU - Jesús Álvarez Rodríguez AU - Pablo Patiño AU - Marina Trigueros AU - Miren Uriarte AU - Alexandra Martín-Ramírez AU - Cristina Arévalo Román AU - José María Galván-Román AU - Rosario García-Vicuña AU - Julio Ancochea AU - Cecilia Muñoz Calleja AU - Elena Fernández-Ruiz AU - Rafael de la Cámara AU - Carmen Suárez Fernández AU - Isidoro González Álvaro AU - Diego A. Rodríguez Serrano AU - on behalf of the PREDINMUN- COVID Group TI - SARS-CoV-2 viremia precedes an IL6 response in severe COVID-19 patients: results of a longitudinal prospective cohort AID - 10.1101/2022.01.24.22269734 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.24.22269734 4099 - http://medrxiv.org/content/early/2022/01/24/2022.01.24.22269734.short 4100 - http://medrxiv.org/content/early/2022/01/24/2022.01.24.22269734.full AB - Background Interleukin 6 (IL6) levels and SARS-CoV-2 viremia have been correlated with COVID-19 severity. The association over time between them has not been assessed in a prospective cohort. Our aim was to evaluate the relationship between SARS-CoV-2 viremia and time evolution of IL6 levels in a COVID-19 prospective cohort.Methods Secondary analysis from a prospective cohort including COVID-19 hospitalized patients from Hospital Universitario La Princesa between November 2020 and January 2021. Serial plasma samples were collected from admission until discharge. Viral load was quantified by Real-Time Polymerase Chain Reaction and IL6 levels with an enzyme immunoassay. To represent the evolution over time of both variables we used the graphic command twoway of Stata.Results A total of 57 patients were recruited, with median age of 63 years (IQR [53-81]), 61.4% male and 68.4% caucasian. The peak of viremia appeared shortly after symptom onset in patients with persistent viremia (more than 1 sample with >1.3 log10 copies/ml) and also in those with at least one IL6>30 pg/ml, followed by a progressive increase in IL6 around 10 days later. Persistent viremia in the first week of hospitalization was associated with higher levels of IL6. Both IL6 and SARS-CoV-2 viral load were higher in males, with a quicker increase with age.Conclusions In those patients with worse outcomes, an early peak of SARS-CoV-2 viral load precedes an increase in IL6 levels. Monitoring SARS-CoV-2 viral load during the first week after symptom onset may be helpful to predict disease severity in COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded with grants: Fondos Supera COVID19 by Banco Santander and CRUE to CS, RG-V, CM and JA; RD16/0011/0012 and PI18/0371 to IGA, from Ministerio de Economia y Competitividad (Instituto de Salud Carlos III) and co-funded by European regional development fund (ERDF) A way to make Europe; and co-financed by the Community of Madrid through the Covid 2019 Aid. The work of ER-V has been funded by a Rio-Hortega grant CM19/00149 from the Ministerio de Economia y Competitividad (Instituto de Salud Carlos III) and co-funded by The European Regional Development Fund (ERDF) A way to make Europe. SR-G was funded by the Spanish Rheumatology Foundation (grants for physicians-researchers 2018-2021). None of these sponsors have had any role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Research Ethics Committee of Hospital Universitario La Princesa, Madrid, (register number 4267; 22-10-2020) and it was carried out following the ethical principles established in the Declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors